- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00521079
EMPOWER Clinical Trial: Vagal Blocking for Obesity Control (EMPOWER)
Study Overview
Detailed Description
The Maestro System is a neuromodulation system that consists of implantable and external components.
Implantable components: two leads (one electrode each for the anterior and posterior intra-abdominal vagal nerve trunks) that are connected to an implantable neuroregulator.
External components: one programmable, battery-powered, ambulatory external controller connected via a small, flexible cable to a cutaneous transmit coil that is positioned externally over the neuroregulator. A clinician programmer that transmits information to the controller and uploads data from the controller.
All non-diabetic subjects will be randomized in a 2:1 allocation to therapy ON or therapy OFF groups. All type 2 diabetes mellitus subjects will be randomized in a 1:1 allocation to therapy ON or therapy OFF groups.
All subjects will receive blinded therapy through the 12-month follow-up visit. All subjects will participate in a medical weight management program.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2153
- Institute of Weight Control
-
-
South Australia
-
Bedford Park, South Australia, Australia, 5042
- Adelaide Bariatric Center - Flinders Private Hospital
-
-
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- HonorHealth (formerly Scottsdale Bariatric Center)
-
-
California
-
La Jolla, California, United States, 92037
- Scripps Clinic
-
Orange, California, United States, 92868
- University of California, Irvine Medical Center
-
Stanford, California, United States, 94305
- Stanford University Medical Center
-
-
Florida
-
Weston, Florida, United States, 33331
- Cleveland Clinic - Florida
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Johns Hopkins
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts New England Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic - Ohio
-
-
Oregon
-
Portland, Oregon, United States, 97239-3098
- Oregon Health & Science University
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Informed consent.
Body mass index (BMI) ≥ 40 kg/m2 to 45 kg/m2 or BMI ≥ 35 kg/m2 to 39.9 kg/m2 with one or more obesity related co-morbid condition. Co-morbid conditions may include one or more of the following:
- Type 2 diabetes mellitus (note: type 2 diabetics are allowed at selected centers only, see Inclusion criterion #5)
- Hypertension as defined by systolic pressure ≥140 mmHg and/or diastolic pressure ≥90 mmHg a) treated or untreated with systolic ≥140 mmHg or diastolic ≥90 mmHg or b) treated with systolic <140 mmHg and diastolic <90 mmHg
- Dyslipidemia as defined by total cholesterol ≥200 or LDL ≥130 a) treated or untreated with total cholesterol ≥200 or LDL ≥130 or b) treated with total cholesterol <200 or LDL <130
- Sleep apnea syndrome (confirmed by overnight p02 studies)
- Obesity related cardiomyopathy
- Females or males Note: females of child-bearing potential must have a negative urine pregnancy test at Screen and also within 14 days of implant procedure followed by physician-approved contraceptive regimen for the duration of the study period.
- 18-65 years of age inclusive.
Type 2 diabetes mellitus subjects (at selected centers, limited to approximately 34 subjects) with:
- Glycosylated hemoglobin (Hb A1c) 6.5 - 9 % inclusive at screening visit.
- Onset: 10 years or less since initial diagnosis.
- Stable treatment regimen: no change in oral hypoglycemic treatment regimen within past 3 months.
- Currently not using insulin therapy, GLP-1 receptor agonists (e.g., exenatide), or DPP-4 inhibitors (e.g., sitagliptin) for diabetes treatment and have not been on these treatments in the past 6 months.
- Creatinine within normal reference range.
- No history of proliferative retinopathy.
- No history of peripheral neuropathy.
- No history of autonomic neuropathy.
- No history of coronary artery disease, with or without angina pectoris.
- No history of peripheral vascular disease.
- Failure to respond to supervised diet/exercise program(s) in which the subject was engaged for at least 6 months within the last five years.
- Ability to complete all study visits and procedures.
Exclusion criteria
- Concurrent chronic pancreatic disease.
- History of Crohn's disease and/or ulcerative colitis.
- History of bariatric surgery, fundoplication, gastric resection or major upper-abdominal surgery (acceptable surgeries include cholecystectomy, hysterectomy).
- History of pulmonary embolism or blood coagulation disorders.
- Clinically significant hiatal hernias known from subject's medical record as or determined by upper endoscopy prior to implant if they have not had one done during the previous 6 months that specifically reported on the presence or absence of hiatal hernia making reference to the Z-line and/or diaphragmatic notch, in order to rule out subjects with hiatal hernia that may require surgical repair (to support exclusion criterion #7).
- Current portal hypertension and/or esophageal varices.
- Intra-operative exclusion: hiatal hernia requiring surgical repair or extensive dissection at esophagogastric junction at time of surgery.
- Treatment with weight-loss prescription drug therapy within the prior three months and the use of prescription drug therapy or the use over-the-counter weight loss preparations for the duration of the trial.
- Smoking cessation within the prior six months.
- Known genetic cause of obesity (e.g., Prader-Willi Syndrome).
- Overall sustained reduction of more than 10% of body weight in the previous 12 months.
- Physician-prescribed pre-operative diet with intent to lose weight prior to surgery (note: a) study subject may continue any personal diet they were on prior to study enrollment [see exclusion criterion #24] b) standardized EMPOWER weight management program to be initiated in all subjects at time of activation, approximately two weeks after implant)
- Current type 1 diabetes mellitus (DM).
- Current or recent history (within 12 months) of ongoing bulimia.
- Current alterations in treatment for thyroid disorders (stable treatment regimen for prior three months acceptable).
- Current alterations in treatment for epilepsy (stable treatment regimen for prior six months acceptable).
- Current treatment for peptic ulcer disease (previous history acceptable).
- Chronic (more than 4 weeks of daily use) treatment with narcotic analgesic drug regimens (treatment with non-steroidal anti-inflammatory drugs acceptable).
- Current alterations in treatment regimens of anti-cholinergic drugs, including tricyclic antidepressants (stable treatment regimen for prior six months acceptable).
- Current medical condition that, in the opinion of the investigator, would make subject unfit for surgery under general anesthesia or that would be exacerbated by intentional weight loss. Some examples include diagnosis of cancer, recent heart attack, recent stroke or recent serious trauma.
- Presence of permanently implanted electrical powered medical device or implanted gastrointestinal device or prosthesis (e.g., pacemakers, implanted defibrillators, neurostimulators etc.).
- Planned or contemplated use of Magnetic Resonance Imaging (MRI) or oncological radiation during the course of the trial.
- Significant psychiatric disorders that, in the opinion of the investigator, may interfere with subject's ability to follow study procedures and/or instructions.
- Current, active member of an organized weight loss program (e.g., Weight Watchers, TOPS).
- Current participant in another weight loss study or other clinical trials.
- Have a friend or family member who is currently participating or is planning to participate in this clinical trial.
Patient reported:
- inability to walk for about 10 minutes without stopping,
- feeling of pain in chest when doing physical activity,
- feeling of pain in chest when not doing physical activity. Note: unless pain in chest in known to be related to upper gastrointestinal disorders such as gastroesophageal reflux disease or heartburn.
- Clinically significant cardiac rhythm disorder that requires either medical and/or surgical intervention (e.g., paroxysmal or chronic atrial fibrillation).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: vBloc
Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).
|
Intermittent, programmable, intra-abdominal vagal blocking device that delivers therapy (Therapy ON)
Other Names:
|
Sham Comparator: Placebo
Subjects implanted with a functional Maestro System device that does NOT deliver therapy (Therapy OFF).
|
Active intra-abdominal placebo device that delivers no therapy (Therapy OFF)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Excess Weight Loss (EWL) With the Maestro System
Time Frame: Baseline and 1 Year
|
Observe at least a 10% greater percentage excess weight loss (%EWL) with vBloc therapy delivered by the Maestro System compared to sham 12 months following randomization using MetLife Method (ideal body weight is calculated based on Metropolitan Height and Weight Tables)
|
Baseline and 1 Year
|
Rate of System and Procedure-related Serious Adverse Events (SAEs).
Time Frame: 1 Year
|
To estimate the rate of serious, system- and procedure-related adverse events associated with the Maestro System.
|
1 Year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving 25% Excess Weight Loss (%EWL)
Time Frame: Baseline and 1 Year
|
To evaluate the percentage of participants achieving 25% excess weight loss from baseline (implant) to 12 months between treatment groups.
|
Baseline and 1 Year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Charles J Billington, MD, VA Medical Center, Minneapolis, MN / University of Minnesota
- Principal Investigator: Michael Sarr, MD, Mayo Clinic
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D00343-000
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Therapy ON
-
University of ValenciaCompleted
-
Hasselt UniversityJessa HospitalUnknown
-
Ospedale Generale Di Zona Moriggia-PelasciniCompleted
-
Universitaire Ziekenhuizen KU LeuvenRecruitingHeart Failure | Cardiomyopathy, Dilated | Left Ventricular Dyssynchrony | Cardiac Remodeling, VentricularBelgium, Switzerland, Germany, France, Poland, Romania, Brazil, Hungary, Latvia, Portugal, Spain
-
Massachusetts General HospitalBeth Israel Deaconess Medical CenterActive, not recruitingCongestive Heart FailureUnited States
-
University Hospital, LilleMinistry of Health, FranceNot yet recruiting
-
Taipei City HospitalCompletedOccupational Therapy | Psychiatric RehabilitationTaiwan
-
Superior UniversityActive, not recruitingComparison of Efficacy of Mirror Therapy vs Mental Imagery in Reduction of Phantom Limb Pain in AKAPPhantom Limb PainPakistan
-
Karolinska InstitutetCompletedObsessive Compulsive DisorderSweden
-
MOA Health Science FoundationCompletedAnemia | Death | Sickle Cell Disease | Infection | Pain Crisis RecurrentCongo, The Democratic Republic of the